Full Text of SB0702 100th General Assembly
SB0702eng 100TH GENERAL ASSEMBLY |
| | SB0702 Engrossed | | LRB100 07354 RLC 17417 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Section 204 as follows: | 6 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 7 | | Sec. 204. (a) The controlled substances listed in this | 8 | | Section are
included in Schedule I. | 9 | | (b) Unless specifically excepted or unless listed in | 10 | | another
schedule, any of the following opiates, including their | 11 | | isomers,
esters, ethers, salts, and salts of isomers, esters, | 12 | | and ethers,
whenever the existence of such isomers, esters, | 13 | | ethers and salts is
possible within the specific chemical | 14 | | designation: | 15 | | (1) Acetylmethadol; | 16 | | (1.1) Acetyl-alpha-methylfentanyl | 17 | | (N-[1-(1-methyl-2-phenethyl)-
| 18 | | 4-piperidinyl]-N-phenylacetamide); | 19 | | (2) Allylprodine; | 20 | | (3) Alphacetylmethadol, except
| 21 | | levo-alphacetylmethadol (also known as levo-alpha-
| 22 | | acetylmethadol, levomethadyl acetate, or LAAM); | 23 | | (4) Alphameprodine; |
| | | SB0702 Engrossed | - 2 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (5) Alphamethadol; | 2 | | (6) Alpha-methylfentanyl
| 3 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 4 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 5 | | propanilido) piperidine; | 6 | | (6.1) Alpha-methylthiofentanyl
| 7 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 8 | | 4-piperidinyl]-N-phenylpropanamide); | 9 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 10 | | (7.1) PEPAP
| 11 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 12 | | (8) Benzethidine; | 13 | | (9) Betacetylmethadol; | 14 | | (9.1) Beta-hydroxyfentanyl
| 15 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 16 | | 4-piperidinyl]-N-phenylpropanamide); | 17 | | (10) Betameprodine; | 18 | | (11) Betamethadol; | 19 | | (12) Betaprodine; | 20 | | (13) Clonitazene; | 21 | | (14) Dextromoramide; | 22 | | (15) Diampromide; | 23 | | (16) Diethylthiambutene; | 24 | | (17) Difenoxin; | 25 | | (18) Dimenoxadol; | 26 | | (19) Dimepheptanol; |
| | | SB0702 Engrossed | - 3 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (20) Dimethylthiambutene; | 2 | | (21) Dioxaphetylbutyrate; | 3 | | (22) Dipipanone; | 4 | | (23) Ethylmethylthiambutene; | 5 | | (24) Etonitazene; | 6 | | (25) Etoxeridine; | 7 | | (26) Furethidine; | 8 | | (27) Hydroxpethidine; | 9 | | (28) Ketobemidone; | 10 | | (29) Levomoramide; | 11 | | (30) Levophenacylmorphan; | 12 | | (31) 3-Methylfentanyl
| 13 | | (N-[3-methyl-1-(2-phenylethyl)-
| 14 | | 4-piperidyl]-N-phenylpropanamide); | 15 | | (31.1) 3-Methylthiofentanyl
| 16 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 17 | | 4-piperidinyl]-N-phenylpropanamide); | 18 | | (32) Morpheridine; | 19 | | (33) Noracymethadol; | 20 | | (34) Norlevorphanol; | 21 | | (35) Normethadone; | 22 | | (36) Norpipanone; | 23 | | (36.1) Para-fluorofentanyl
| 24 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 25 | | 4-piperidinyl]propanamide); | 26 | | (37) Phenadoxone; |
| | | SB0702 Engrossed | - 4 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (38) Phenampromide; | 2 | | (39) Phenomorphan; | 3 | | (40) Phenoperidine; | 4 | | (41) Piritramide; | 5 | | (42) Proheptazine; | 6 | | (43) Properidine; | 7 | | (44) Propiram; | 8 | | (45) Racemoramide; | 9 | | (45.1) Thiofentanyl
| 10 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 11 | | 4-piperidinyl]-propanamide); | 12 | | (46) Tilidine; | 13 | | (47) Trimeperidine; | 14 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 15 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 16 | | N-phenylpropanamide). | 17 | | (c) Unless specifically excepted or unless listed in | 18 | | another
schedule, any of the following opium derivatives, its | 19 | | salts, isomers
and salts of isomers, whenever the existence of | 20 | | such salts, isomers and
salts of isomers is possible within the | 21 | | specific chemical designation: | 22 | | (1) Acetorphine; | 23 | | (2) Acetyldihydrocodeine; | 24 | | (3) Benzylmorphine; | 25 | | (4) Codeine methylbromide; | 26 | | (5) Codeine-N-Oxide; |
| | | SB0702 Engrossed | - 5 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (6) Cyprenorphine; | 2 | | (7) Desomorphine; | 3 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 4 | | (9) Dihydromorphine; | 5 | | (10) Drotebanol; | 6 | | (11) Etorphine (except hydrochloride salt); | 7 | | (12) Heroin; | 8 | | (13) Hydromorphinol; | 9 | | (14) Methyldesorphine; | 10 | | (15) Methyldihydromorphine; | 11 | | (16) Morphine methylbromide; | 12 | | (17) Morphine methylsulfonate; | 13 | | (18) Morphine-N-Oxide; | 14 | | (19) Myrophine; | 15 | | (20) Nicocodeine; | 16 | | (21) Nicomorphine; | 17 | | (22) Normorphine; | 18 | | (23) Pholcodine; | 19 | | (24) Thebacon. | 20 | | (d) Unless specifically excepted or unless listed in | 21 | | another
schedule, any material, compound, mixture, or | 22 | | preparation which contains
any quantity of the following | 23 | | hallucinogenic substances, or which
contains any of its salts, | 24 | | isomers and salts of isomers, whenever the
existence of such | 25 | | salts, isomers, and salts of isomers is possible
within the | 26 | | specific chemical designation (for the purposes of this
|
| | | SB0702 Engrossed | - 6 - | LRB100 07354 RLC 17417 b |
|
| 1 | | paragraph only, the term "isomer" includes the optical, | 2 | | position and
geometric isomers): | 3 | | (1) 3,4-methylenedioxyamphetamine
| 4 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 5 | | methylenedioxyamphetamine, MDA); | 6 | | (1.1) Alpha-ethyltryptamine
| 7 | | (some trade or other names: etryptamine;
| 8 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 9 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 10 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 11 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| 12 | | (also known as: N-ethyl-alpha-methyl-
| 13 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 14 | | and MDEA); | 15 | | (2.2) N-Benzylpiperazine (BZP); | 16 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | 17 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 18 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 19 | | (5) (Blank); | 20 | | (6) Diethyltryptamine (DET); | 21 | | (7) Dimethyltryptamine (DMT); | 22 | | (7.1) 5-Methoxy-diallyltryptamine; | 23 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 24 | | (9) Ibogaine (some trade and other names:
| 25 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 26 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
| | | SB0702 Engrossed | - 7 - | LRB100 07354 RLC 17417 b |
|
| 1 | | indole; Tabernanthe iboga); | 2 | | (10) Lysergic acid diethylamide; | 3 | | (10.1) Salvinorin A; | 4 | | (10.5) Salvia divinorum (meaning all parts of the plant | 5 | | presently classified
botanically as Salvia divinorum, | 6 | | whether growing or not, the
seeds thereof, any extract from | 7 | | any part of that plant, and every compound,
manufacture, | 8 | | salts, isomers, and salts of
isomers whenever the existence | 9 | | of such salts, isomers, and salts of
isomers is possible | 10 | | within the specific chemical designation, derivative, | 11 | | mixture, or preparation of that plant, its
seeds or | 12 | | extracts);
| 13 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 14 | | (12) Peyote (meaning all parts of the plant presently | 15 | | classified
botanically as Lophophora williamsii
Lemaire, | 16 | | whether growing or not, the
seeds thereof, any extract from | 17 | | any part of that plant, and every compound,
manufacture, | 18 | | salts, derivative, mixture, or preparation of that plant, | 19 | | its
seeds or extracts); | 20 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 21 | | (14) N-methyl-3-piperidyl benzilate; | 22 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 23 | | (also known as N-hydroxy-alpha-methyl-
| 24 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 25 | | (15) Parahexyl; some trade or other names:
| 26 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
| | | SB0702 Engrossed | - 8 - | LRB100 07354 RLC 17417 b |
|
| 1 | | dibenzo (b,d) pyran; Synhexyl; | 2 | | (16) Psilocybin; | 3 | | (17) Psilocyn; | 4 | | (18) Alpha-methyltryptamine (AMT); | 5 | | (19) 2,5-dimethoxyamphetamine
| 6 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 7 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 8 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 9 | | 4-bromo-2,5-DMA); | 10 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 11 | | Some trade or other names: 2-(4-bromo-
| 12 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 13 | | alpha-desmethyl DOB, 2CB, Nexus; | 14 | | (21) 4-methoxyamphetamine
| 15 | | (4-methoxy-alpha-methylphenethylamine;
| 16 | | paramethoxyamphetamine; PMA); | 17 | | (22) (Blank); | 18 | | (23) Ethylamine analog of phencyclidine.
| 19 | | Some trade or other names:
| 20 | | N-ethyl-1-phenylcyclohexylamine,
| 21 | | (1-phenylcyclohexyl) ethylamine,
| 22 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 23 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 24 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 25 | | PHP; | 26 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
| | | SB0702 Engrossed | - 9 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 2 | | (another name: DOET); | 3 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 4 | | (another name: TCPy); | 5 | | (28) (Blank); | 6 | | (29) Thiophene analog of phencyclidine (some trade
| 7 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 8 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 9 | | (30) Bufotenine (some trade or other names:
| 10 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 11 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 12 | | 5-hydroxy-N,N-dimethyltryptamine;
| 13 | | N,N-dimethylserotonin; mappine); | 14 | | (31) 1-Pentyl-3-(1-naphthoyl)indole | 15 | | Some trade or other names: JWH-018; | 16 | | (32) 1-Butyl-3-(1-naphthoyl)indole | 17 | | Some trade or other names: JWH-073; | 18 | | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- | 19 | | (2-iodophenyl)methanone | 20 | | Some trade or other names: AM-694; | 21 | | (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | 22 | | (2-methyloctan-2-yl)phenol | 23 | | Some trade or other names: CP 47,497 | 24 | | and its C6, C8 and C9 homologs; | 25 | | (34.5) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | 26 | | (2-methyloctan-2-yl)phenol), where side chain n=5; |
| | | SB0702 Engrossed | - 10 - | LRB100 07354 RLC 17417 b |
|
| 1 | | and homologues where side chain n=4, 6, or 7; Some | 2 | | trade or other names: CP 47,497; | 3 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 4 | | (2-methyloctan-2-yl)-6a,7, | 5 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 6 | | Some trade or other names: HU-210; | 7 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | 8 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | 9 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 10 | | salts, and salts of isomers; Some trade or other | 11 | | names: HU-210, Dexanabinol; | 12 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 13 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 14 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 15 | | Some trade or other names: HU-211; | 16 | | (37) (2-methyl-1-propyl-1H-indol- | 17 | | 3-yl)-1-naphthalenyl-methanone | 18 | | Some trade or other names: JWH-015; | 19 | | (38) 4-methoxynaphthalen-1-yl- | 20 | | (1-pentylindol-3-yl)methanone | 21 | | Some trade or other names: JWH-081; | 22 | | (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole | 23 | | Some trade or other names: JWH-122; | 24 | | (40) 2-(2-methylphenyl)-1-(1-pentyl- | 25 | | 1H-indol-3-yl)-ethanone | 26 | | Some trade or other names: JWH-251; |
| | | SB0702 Engrossed | - 11 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (41) 1-(2-cyclohexylethyl)-3- | 2 | | (2-methoxyphenylacetyl)indole | 3 | | Some trade or other names: RCS-8, BTW-8 and SR-18; | 4 | | (42) Any compound structurally derived from | 5 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl- | 6 | | (1-naphthyl)methane by substitution at the | 7 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 8 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 9 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | 10 | | or 2-(4-morpholinyl)ethyl whether or not further | 11 | | substituted in the indole ring to any extent, whether | 12 | | or not substituted in the naphthyl ring to any extent. | 13 | | Examples of this structural class include, but are | 14 | | not limited to, JWH-018, AM-2201, JWH-175, JWH-184, | 15 | | and JWH-185; | 16 | | (43) Any compound structurally derived from | 17 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | 18 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 19 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | 20 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | 21 | | or 2-(4-morpholinyl)ethyl, whether or not further | 22 | | substituted in the pyrrole ring to any extent, whether | 23 | | or not substituted in the naphthyl ring to any extent. | 24 | | Examples of this structural class include, but are not | 25 | | limited to, JWH-030, JWH-145, JWH-146, JWH-307, and | 26 | | JWH-368; |
| | | SB0702 Engrossed | - 12 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (44) Any compound structurally derived from | 2 | | 1-(1-naphthylmethyl)indene by substitution | 3 | | at the 3-position of the indene ring by alkyl, haloalkyl, | 4 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 5 | | halide, alkyl aryl halide, 1-(N-methyl- | 6 | | 2-piperidinyl)methyl, or 2-(4- | 7 | | morpholinyl)ethyl whether or not further substituted in | 8 | | the indene ring to any extent, whether or not substituted | 9 | | in the naphthyl ring to any extent. Examples of | 10 | | this structural class include, but are not | 11 | | limited to, JWH-176; | 12 | | (45) Any compound structurally derived from | 13 | | 3-phenylacetylindole by substitution at the | 14 | | nitrogen atom of the indole ring with alkyl, haloalkyl, | 15 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 16 | | halide, alkyl aryl halide, 1-(N-methyl-2- | 17 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 18 | | whether or not further substituted in the indole ring | 19 | | to any extent, whether or not substituted in the phenyl | 20 | | ring to any extent. Examples of this structural | 21 | | class include, but are not limited to, JWH-167, | 22 | | JWH-250, JWH-251, and RCS-8; | 23 | | (46) Any compound structurally derived from | 24 | | 2-(3-hydroxycyclohexyl)phenol by substitution | 25 | | at the 5-position of the phenolic ring by alkyl, | 26 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
| | | SB0702 Engrossed | - 13 - | LRB100 07354 RLC 17417 b |
|
| 1 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | 2 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 3 | | whether or not substituted in the cyclohexyl ring to any | 4 | | extent. Examples of this structural class | 5 | | include, but are not limited to, CP 47, | 6 | | 497 and its C8 homologue (cannabicyclohexanol); | 7 | | (46.1) Benzoylindoles: Any compound | 8 | | containing a 3-(benzoyl) indole structure with | 9 | | substitution at the nitrogen atom of the | 10 | | indole ring by an alkyl, haloalkyl, alkenyl, | 11 | | cycloalkylmethyl, cycloalkylethyl, | 12 | | 1-(N-methyl-2-piperidinyl)methyl, | 13 | | or 2-(4-morpholinyl)ethyl group | 14 | | whether or not further substituted | 15 | | in the indole ring to any extent and | 16 | | whether or not substituted in the phenyl ring | 17 | | to any extent. Examples of this structural class | 18 | | include, but are not limited , to , AM-630, | 19 | | AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; | 20 | | (47) 3,4-Methylenedioxymethcathinone | 21 | | Some trade or other names: Methylone; | 22 | | (48) 3,4-Methyenedioxypyrovalerone | 23 | | Some trade or other names: MDPV; | 24 | | (49) 4-Methylmethcathinone | 25 | | Some trade or other names: Mephedrone; | 26 | | (50) 4-methoxymethcathinone; |
| | | SB0702 Engrossed | - 14 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (51) 4-Fluoromethcathinone; | 2 | | (52) 3-Fluoromethcathinone; | 3 | | (53) 2,5-Dimethoxy-4-(n)-propylthio- | 4 | | phenethylamine; | 5 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; | 6 | | (55) Pentedrone; | 7 | | (56) 4-iodo-2,5-dimethoxy-N-((2-methoxy | 8 | | phenyl)methyl)-benzeneethanamine | 9 | | (trade or other name: 25I-NBOMe); | 10 | | (57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl) | 11 | | methyl]-benzeneethanamine (trade or other name: | 12 | | 25C-NBOMe); | 13 | | (58) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl) | 14 | | methyl]-benzeneethanamine (trade or other name: | 15 | | 25B-NBOMe); | 16 | | (59) 3-cyclopropoylindole with | 17 | | substitution at the nitrogen atom of the | 18 | | indole ring by alkyl, haloalkyl, alkenyl, | 19 | | cycloalkylmethyl, cycloalkylethyl, aryl | 20 | | halide, alkyl aryl halide, | 21 | | 1-(N-methyl-2-piperidinyl)methyl, or | 22 | | 2-(4-morpholinyl)ethyl, whether or not | 23 | | further substituted on the indole ring | 24 | | to any extent, whether or not substituted | 25 | | on the cyclopropyl ring to any extent: | 26 | | including , but not limited to , XLR11, |
| | | SB0702 Engrossed | - 15 - | LRB100 07354 RLC 17417 b |
|
| 1 | | UR144, FUB-144; | 2 | | (60) 3-adamantoylindole with | 3 | | substitution at the nitrogen atom of the | 4 | | indole ring by alkyl, haloalkyl, alkenyl, | 5 | | cycloalkylmethyl, cycloalkylethyl, | 6 | | aryl halide, alkyl aryl halide, | 7 | | 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not | 9 | | further substituted on the indole ring to | 10 | | any extent, whether or not substituted on | 11 | | the adamantyl ring to any extent: including , | 12 | | but not limited to , AB-001; | 13 | | (61) N-(adamantyl)-indole-3-carboxamide | 14 | | with substitution at the nitrogen atom of the | 15 | | indole ring by alkyl, haloalkyl, alkenyl, | 16 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, | 17 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | 18 | | or 2-(4-morpholinyl)ethyl, whether or not further | 19 | | substituted on the indole ring to any extent, whether | 20 | | or not substituted on the adamantyl ring to any | 21 | | extent: including , but not limited to , | 22 | | APICA/2NE-1, STS-135; | 23 | | (62) N-(adamantyl)-indazole-3-carboxamide | 24 | | with substitution at a nitrogen atom of the indazole | 25 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 26 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
| | | SB0702 Engrossed | - 16 - | LRB100 07354 RLC 17417 b |
|
| 1 | | 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further | 3 | | substituted on the indazole ring to any extent, | 4 | | whether or not substituted on the adamantyl | 5 | | ring to any extent: including , but not limited | 6 | | to , AKB48, 5F-AKB48; | 7 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl | 8 | | ester with substitution at the nitrogen atom of the | 9 | | indole ring by alkyl, haloalkyl, alkenyl, | 10 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | 11 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 12 | | 2-(4-morpholinyl)ethyl, whether or not further | 13 | | substituted on the indole ring to any extent, | 14 | | whether or not substituted on the quinoline ring | 15 | | to any extent: including , but not limited to , PB22, | 16 | | 5F-PB22, FUB-PB-22; | 17 | | (64) 3-(1-naphthoyl)indazole with | 18 | | substitution at the nitrogen atom of the | 19 | | indazole ring by alkyl, haloalkyl, | 20 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, | 21 | | aryl halide, alkyl aryl halide, | 22 | | 1-(N-methyl-2-piperidinyl)methyl, or | 23 | | 2-(4-morpholinyl)ethyl, whether or not further | 24 | | substituted on the indazole ring to any extent, | 25 | | whether or not substituted on the naphthyl ring | 26 | | to any extent: including , but not limited to , |
| | | SB0702 Engrossed | - 17 - | LRB100 07354 RLC 17417 b |
|
| 1 | | THJ-018, THJ-2201; | 2 | | (65) 2-(1-naphthoyl)benzimidazole with | 3 | | substitution at the nitrogen atom of the benzimidazole | 4 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 5 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 6 | | 1-(N-methyl-2-piperidinyl)methyl, or | 7 | | 2-(4-morpholinyl)ethyl, whether or not further | 8 | | substituted on the benzimidazole ring to any extent, | 9 | | whether or not substituted on the naphthyl ring to | 10 | | any extent: including, but not limited to , FUBIMINA; | 11 | | (66) N-(1-amino-3-methyl-1-oxobutan-2-yl) | 12 | | -1H-indazole-3-carboxamide with substitution on the | 13 | | nitrogen atom of the indazole ring by alkyl, | 14 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 15 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | 16 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 17 | | whether or not further substituted on the indazole | 18 | | ring to any extent: including , but not limited to , | 19 | | AB-PINACA, AB-FUBINACA, AB-CHMINACA; | 20 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan- | 21 | | 2-yl)-1H-indazole-3-carboxamide with substitution | 22 | | on the nitrogen atom of the indazole ring by alkyl, | 23 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 24 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | 25 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether | 26 | | or not further substituted on the indazole ring to any |
| | | SB0702 Engrossed | - 18 - | LRB100 07354 RLC 17417 b |
|
| 1 | | extent: including , but not limited to , | 2 | | ADB-PINACA, ADB-FUBINACA; | 3 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- | 4 | | 1H-indole-3-carboxamide with substitution on the nitrogen | 5 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, | 6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | 7 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further | 9 | | substituted on the indole ring to any extent: | 10 | | including , but not limited to , ADBICA, 5F-ADBICA; | 11 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- | 12 | | 1H-indole-3-carboxamide with substitution on the | 13 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 14 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 15 | | halide, alkyl aryl halide, 1-(N-methyl-2- | 16 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 17 | | whether or not further substituted on the indole | 18 | | ring to any extent: including , but not limited | 19 | | to , ABICA, 5F-ABICA; | 20 | | (70) Methyl 2-(1H-indazole-3-carboxamido)- | 21 | | 3-methylbutanoate with substitution on the nitrogen | 22 | | atom of the indazole ring by alkyl, haloalkyl, | 23 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 24 | | halide, alkyl aryl halide, 1-(N-methyl-2- | 25 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 26 | | whether or not further substituted on the indazole |
| | | SB0702 Engrossed | - 19 - | LRB100 07354 RLC 17417 b |
|
| 1 | | ring to any extent: including , but not | 2 | | limited to , AMB, 5F-AMB ; . | 3 | | (71) 3,4-Dichloro-N-[2-(dimethylamino) | 4 | | cyclohexyl]-N-methylbenzamide (Some trade or other | 5 | | name: U-47700). | 6 | | (e) Unless specifically excepted or unless listed in | 7 | | another
schedule, any material, compound, mixture, or | 8 | | preparation which contains
any quantity of the following | 9 | | substances having a depressant effect on
the central nervous | 10 | | system, including its salts, isomers, and salts of
isomers | 11 | | whenever the existence of such salts, isomers, and salts of
| 12 | | isomers is possible within the specific chemical designation: | 13 | | (1) mecloqualone; | 14 | | (2) methaqualone; and | 15 | | (3) gamma hydroxybutyric acid. | 16 | | (f) Unless specifically excepted or unless listed in | 17 | | another schedule,
any material, compound, mixture, or | 18 | | preparation which contains any quantity
of the following | 19 | | substances having a stimulant effect on the central nervous
| 20 | | system, including its salts, isomers, and salts of isomers: | 21 | | (1) Fenethylline; | 22 | | (2) N-ethylamphetamine; | 23 | | (3) Aminorex (some other names:
| 24 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 25 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 26 | | salts, optical isomers, and salts of optical isomers; |
| | | SB0702 Engrossed | - 20 - | LRB100 07354 RLC 17417 b |
|
| 1 | | (4) Methcathinone (some other names:
| 2 | | 2-methylamino-1-phenylpropan-1-one;
| 3 | | Ephedrone; 2-(methylamino)-propiophenone;
| 4 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 5 | | methycathinone; Monomethylpropion; UR 1431) and its
| 6 | | salts, optical isomers, and salts of optical isomers; | 7 | | (5) Cathinone (some trade or other names:
| 8 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 9 | | 2-amino-1-phenyl-propanone; norephedrone); | 10 | | (6) N,N-dimethylamphetamine (also known as:
| 11 | | N,N-alpha-trimethyl-benzeneethanamine;
| 12 | | N,N-alpha-trimethylphenethylamine); | 13 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 14 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 15 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV). | 16 | | (g) Temporary listing of substances subject to emergency | 17 | | scheduling.
Any material, compound, mixture, or preparation | 18 | | that contains any quantity
of the following substances: | 19 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| 20 | | (benzylfentanyl), its optical isomers, isomers, salts,
| 21 | | and salts of isomers; | 22 | | (2) N-[1(2-thienyl)
| 23 | | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| 24 | | its optical isomers, salts, and salts of isomers. | 25 | | (h) Synthetic cathinones. Unless specifically excepted, | 26 | | any chemical compound not including bupropion, structurally |
| | | SB0702 Engrossed | - 21 - | LRB100 07354 RLC 17417 b |
|
| 1 | | derived from 2-aminopropan-1-one by substitution at the | 2 | | 1-position with either phenyl, naphthyl, or thiophene ring | 3 | | systems, whether or not the compound is further modified in one | 4 | | or more of the following ways: | 5 | | (1) by substitution in the ring system to | 6 | | any extent with alkyl, alkylenedioxy, alkoxy, | 7 | | haloalkyl, hydroxyl, or halide substituents, whether | 8 | | or not further substituted in the ring system | 9 | | by one or more other univalent substituents. | 10 | | Examples of this class include, but are not | 11 | | limited to, 3,4-Methylenedioxycathinone | 12 | | (bk-MDA); | 13 | | (2) by substitution at the 3-position | 14 | | with an acyclic alkyl substituent. Examples of | 15 | | this class include, but are not limited to, | 16 | | 2-methylamino-1-phenylbutan-1-one | 17 | | (buphedrone); or | 18 | | (3) by substitution at the 2-amino nitrogen | 19 | | atom with alkyl, dialkyl, benzyl, or methoxybenzyl | 20 | | groups, or by inclusion of the 2-amino nitrogen atom | 21 | | in a cyclic structure. Examples of this class include, | 22 | | but are not limited to, Dimethylcathinone, Ethcathinone, | 23 | | and a-Pyrrolidinopropiophenone (a-PPP). | 24 | | (Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised | 25 | | 10-25-16.)
| 26 | | Section 99. Effective date. This Act takes effect upon |
| | | SB0702 Engrossed | - 22 - | LRB100 07354 RLC 17417 b |
|
| 1 | | becoming law.
|
|